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ABSTRACT 
Pycnogenol
®
 (PYC) is a standardized bark extract from French maritime pine (Pinus 
pinaster Aiton). We examined the inhibitory effects of PYC on alveolar bone resorption, 
which is a characteristic feature of periodontitis, induced by Porphyromonas gingivalis 
(P. gingivalis) and osteoclast differentiation. In rat periodontitis model, rats were 
divided into four groups: group A served as the non-infected control, group B was 
infected orally with P. gingivalis ATCC 33277, group C was administered PYC in the 
diet (0.025%: w/w), and group D was infected with P. gingivalis and administered PYC. 
Administration of PYC along with P. gingivalis infection significantly reduced alveolar 
bone resorption. Treatment of P. gingivalis with 1 µg/ml PYC reduced the number of 
viable bacterial cells. Addition of PYC to epithelial cells inhibited adhesion and 
invasion by P. gingivalis. The effect of PYC on osteoclast formation was confirmed by 
tartrate-resistant acid phosphatase (TRAP) staining. PYC treatment significantly 
inhibited osteoclast formation. Addition of PYC (1-100 μg/ml) to purified osteoclasts 
culture induced cell apoptosis. These results suggest that PYC may prevent alveolar 
bone resorption through its antibacterial activity against P. gingivalis and by suppressing 
osteoclastogenesis. Therefore, PYC may be useful as a therapeutic and preventative 
agent for bone diseases such as periodontitis. 
4 
 
INTRODUCTION 
Periodontal diseases are chronic inflammatory disorders of bacterial origin 
characterized by loss of alveolar bone and destruction of connective tissue supporting 
the teeth
 
(Cochran, 2008; Highfield, 2009). These diseases are mixed infections induced 
by a specific group of Gram-negative anaerobic bacteria (Feng et al., 2006; Haffajee et 
al., 1994). Among over 700 bacterial species that have been identified in the oral cavity, 
Porphyromonas gingivalis (P. gingivalis), a black-pigmented Gram-negative anaerobe, 
has been recognized as one of the most important causative microorganism in chronic 
periodontitis. The initial event in most infectious diseases involves the adhesion of 
pathogens to host tissues and subsequent invasion by the pathogens. P. gingivalis can 
adhere to and invade epithelial cells, which is thought to facilitate retention in the oral 
environment and contribute to immune evasion and tissue destruction. Furthermore, P. 
gingivalis produces a number of virulence factors including fimbriae, adhesins, capsular 
polysaccharide and lipopolysaccharide as well as numerous proteases that contribute to 
host colonization, immune defense system neutralization and periodontal tissue 
destruction (Hamada et al., 2007; Holt et al., 2005). 
Plant polyphenols have attracted a good deal of attention for their potential human 
health benefits and clinical uses (Pandey et al., 2009). Extensive studies have been 
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carried out and indicated that intake of polyphenols may prevent some types of cancers, 
cardiovascular diseases and other disorders associated with oxidative stress, owing to 
their antioxidant properties (Scalbert et al., 2005; El Gharras, 2009). Furthermore, 
polyphenols have been reported to possess antimicrobial and anti-inflammatory 
characteristics (Scalbert et al., 2005; El Gharras, 2009). Because periodontal diseases 
are associated with pathogenic bacteria and causing tissue inflammation around the 
teeth, polyphenols may be of interest as preventive and therapeutic agents. 
Pycnogenol
®
 (PYC) is a standardized bark extract of the French maritime pine 
Pinus pinaster (formerly known as Pinus maritime) Aiton, which grows in the coastal 
region of southwest France. Approximately 65-75% of PYC extract consists of 
procyanidins comprising catechin and epicatechin subunits of varying chain lengths. 
Other constituents include polyphenolic monomers, phenolic or cinnamic acids and 
their glycosides (Rohdewald, 2002). The quality of this extract is specified in the United 
States Pharmacopeia (USP 28). The whole extract and individual fraction have been 
shown to have strong antioxidant capacity in in vitro cultured cells, perfused organs and 
in vivo models (Packer et al., 1999). Cho et al. reported that an extract from Pinus 
maritime inhibited the gene expression of proinflammatory cytokines in RAW 264.7 
cells (Cho et al., 2006). In human studies, PYC was also demonstrated diverse 
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anti-inflammatory actions. Double-blind, placebo-controlled studies in asthma patients 
showed reduced plasma or urine leukotriene concentrations after PYC supplementation, 
while asthma symptom scores and pulmonary function improved (Rohdewald, 2002; 
Hosseini et al., 2001; Lau et al., 2004). Another report showed that symptoms of 
chronic venous insufficiency such as pain and edema decreased (Arcangeli, 2000). With 
respect to the effectiveness of PYC for periodontal diseases, little information is 
available except the report by Kimbrough et al. about PYC-containing chewing gum, 
which minimized gingival bleeding and plaque formation (Kimbrough et al., 2002). The 
purpose of the present study was to investigate the antibacterial effects of PYC against P. 
gingivalis, the inhibitory effects on the experimental periodontitis in rats induced by P. 
gingivalis and in vitro osteoclast differentiation in order to evaluated PYC as a 
preventive and therapeutic agent for periodontal diseases. 
 
 
MATERIALS AND METHODS 
Preparation of PYC 
PYC powder (French maritime pine bark extract) was provided by Tradepia Co. (Tokyo, 
Japan). PYC was dissolved in distilled water, sterilized through a 0.45 μm filtration 
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membrane and serially diluted with phosphate-buffered saline (PBS, pH 7.4) or cell 
culture media. In order to determine the effect of the extract on experimental 
periodontitis in rats, PYC was mixed into standardized diet as a hard briquette at 
0.025% (wt/wt) concentration by Oriental Yeast Co., Ltd. (Tokyo, Japan), the dose level 
of which was estimated to equivalent to a human intake level. 
 
Bacterial strains and growth conditions 
The bacterial strain used in this study was P. gingivalis ATCC 33277. P. gingivalis was 
grown in brain heart infusion broth (BHI broth; Becton Dickinson Co., Sparks, MD, 
USA) supplemented with 5 mg/ml yeast extract, 5 μg/ml hemin and 1 µg/ml vitamin K1 
(BHIY-HK broth) at 37°C for 18 h under anaerobic conditions (85% N2, 10% H2, 5% 
CO2). 
 
Experimental periodontitis in rats 
Twenty-four male, specific-pathogen free, 4-week-old, Sprague-Dawley rats, each 
weighing approximately 80 g, were obtained from a commercial farm (Nihon SLC, 
Shizuoka, Japan). The rats were provided with water and fed a standardized diet or 
standardized diet supplemented with PYC as hard briquettes, both provided by Oriental 
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Yeast. The animals were maintained in a 12-h light-dark cycle (lights on 08:00–20:00) 
at a temperature of 22°C and relative humidity of 50%. Rats were given 
sulfamethoxazole
 
(1 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) and trimethoprim
 
(200 μg/ml; Sigma) in drinking water for 4 days to reduce the original oral flora, 
followed by a 3-day antibiotic-free period before being challenged with P. gingivalis. 
The rats were divided randomly into the following four groups of six rats each (Fig. 1). 
Group A received only 5% carboxymethylcellulose (CMC; Sigma). Group B was 
infected orally with P. gingivalis ATCC 33277 suspended in 5% CMC, and each rat 
received 0.5 ml (3.0 × 10
9
 colony-forming units (CFU)/ml) by oral gavage five times at 
48-h intervals. Group C was administered PYC in the diet, and Group D was infected 
orally with P. gingivalis and administered PYC. Each group of six animals was kept in a 
cage throughout the experimental period to facilitate successful isolation. Thirty-four 
days after the final infection, all rats were sacrificed under general anesthesia. The 
experimental procedures in this study were reviewed and approved by the Committee of 
Ethics on Animal Experiments of Kanagawa Dental University and were carried out 
under the guidelines for animal experimentation of Kanagawa Dental University, which 
are in accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
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Measurement of alveolar bone resorption 
The upper jaws were defleshed by treatment after 10 min in an autoclave at 
15 pounds/inch
2
, and then immersed in 3% hydrogen peroxide, rinsed, air-dried and 
stained with 1% methylene blue. The distance between the cemento-enamel junction 
(CEJ) and the alveolar bone crest (ABC) around the maxillary molars was measured at 
seven buccal sites per rat and horizontal alveolar bone resorption was evaluated. 
Measurements were made using a dissecting microscope (×40) fitted with a digital 
high-definition system (digital HD microscope VH-7000; Keyence, Osaka, Japan) that 
was standardized to provide measurements in millimeters (Fig. 3A). 
 
Antibacterial activity against P. gingivalis 
Exponentially growing P. gingivalis cells were washed and suspended in PBS to an 
optical density of 1.0 at 600 nm, which equated to approximately 4 × 10
9
 CFU/ml. Ten 
μl of bacterial suspension was exposed for 1, 10, and 60 min to 1 ml of 1 µg/ml, 10 
µg/ml, 100 µg/ml or 1000 µg/ml PYC, or the same volume of PBS as a control. After 
the PYC treatment, P. gingivalis cells suspension was serially diluted and 100 μl of each 
dilution was spread onto a BHIY-HK sheep blood agar plate. The number of CFU was 
determined after 7 days’ incubation in an anaerobic atmosphere. Each experiment was 
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carried out three times, and the results were shown with the mean value of the 
experiments. Bactericidal activity was defined as a reduction in viable bacteria of 
>3log10 CFU/ml at any of the incubation periods tested.  
 
Human gingival epithelial cell cultures 
Primary cultures of human gingival epithelial cells (HGECs) were prepared as follows. 
Briefly, healthy gingival tissues were collected during oral surgery from dental patients 
for the removal of impacted third molars with their informed consent. The tissues were 
digested with 0.4% dispase (Godoshusei, Tokyo, Japan) overnight at 4°C. The surface 
epithelium was separated and dissociated further in 0.05% trypsin solution (GIBCO, 
Buffalo, NY, USA) into single-cell suspensions. The cells were collected and suspended 
in keratinocyte growth medium (KGM; LONZA, Walkersville, MD, USA) and 
incubated at 37°C under 5% CO2 until confluent. The cells were suspended in trypsin 
and seeded at 4 × 10
4
 cell per well in a 24-well culture with KGM. After 48-h 
incubation, the cells were grown to near confluency (10
5
 cells/well) and used for 
adherence and invasion assays. 
 
Adherence and invasion assays 
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Adherence to and invasion of HGECs by P. gingivalis was assessed using an antibiotics 
protection assay. The P. gingivalis culture was centrifuged, washed with KGM and 
resuspended in KGM at a final concentration of 10
9
 cells/ml. Bacterial suspensions were 
added to confluent HGEC monolayers at a multiplicity of infection (MOI) of 100 and 
incubated at 37°C in 5% CO2 for 90 min. After incubation, unattached bacteria were 
removed by washing of the monolayers twice with sterile PBS. HGECs were lysed in 1 
ml of sterile distilled water per well and incubated for 30 min. Lysates were serially 
diluted, plated on BHIY-HK blood agar plates and incubated anaerobically at 37°C for 7 
days. 
Invasion of HGECs by P. gingivalis was quantified by determining the number of 
CFU recovered after antibiotic treatment. Confluent HGEC monolayers, infected with P. 
gingivalis (MOI = 100) and incubated for 90 min, were washed with PBS twice. 
External adherent bacteria were killed by incubating with KGM containing gentamicin 
(300 μg/ml) and metronidazole (200 μg/ml) for an additional 60 min. The monolayers 
were rinsed again with PBS before lysis in sterile water. Internalized bacteria were 
enumerated on BHIY-HK blood agar plates. The inhibitory effects of PYC on P. 
gingivalis adherence and invasion to HGECs were examined by adding various 
concentrations of PYC to the HGEC cultures 60 min prior to bacterial infection. All 
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assays were performed in triplicate. 
 
Cell viability assay 
Cell viability in MC3T3-G2/PA6 (PA6) cells (RIKEN Cell Bank, Tsukuba, Japan) was 
determined by the CellTiter 96
®
 Aqueous Non-Radioactive Cell Proliferation Assay 
(Promega Co., Madison, WI, USA) according to the manufacture’s instructions. In brief, 
PA6 cells were placed in 96-well plates at a concentration of 1 × 10
4
 cells/well and were 
grown in alpha-Minimum essential medium (α-MEM) (GIBCO) containing 20% fetal 
bovine serum
 
(FBS; SAFC Biosciences, Denver, CO, USA) to sub-confluence. The cells 
were then treated with 0.1 μg/ml, 1 μg/ml, 10 μg/ml, 100 μg/ml or 500 μg/ml PYC. 
After 48 h incubation, the absorbance was measured at 490 nm. Results are expressed as 
the mean ± standard deviation (SD) of the relative percentage of viability compared 
with negative controls without PYC (n = 5). 
 
Osteoclast differentiation assay 
PA6 cells were used in this assay. The function of the cells was similar to bone 
marrow-derived stromal cells that promote osteoclast differentiation when co-cultured 
with spleen cells in the presence of 1α,25-dehydroxyvitamin D3 [1α,25-(OH)2D3] and 
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dexamethasone (Udagawa et al., 1989). Bone marrow cells (1.5 × 10
5
 cells/well), 
obtained from the tibiae of 5- to 8-week-old BALB/c mice, and PA6 cells (1.5 × 10
4
 
cells/well) were co-cultured in α-MEM with 20% FBS for 7 days in the presence of 
10
-8
 M 1α,25-(OH)2D3 (Calcitriol; Wako Pure Chemical Industries, Osaka, Japan) and 
10
-8
 M dexamethasone (Sigma) in 48-well plates in a 5% CO2 atmosphere. The 
inhibitory effects of PYC on osteoclast formation was assessed by adding PYC to the 
culture at the indicated final concentrations. After 7 days incubation, the co-cultured 
cells were stained for tartrate-resistant acid phosphatase (TRAP), a marker enzyme of 
osteoclasts. TRAP-positive multinucleated cells containing three of more nuclei were 
counted as osteoclasts. Results were expressed as the means ± SD of triplicate cultures. 
 
Survival assay 
BALB/c mouse bone marrow cells (1.5 × 10
7
 cells) and PA6 cells (1.5 × 10
6
 cells) were 
co-cultured in α-MEM supplemented with 10% FBS, 1α,25-(OH)2D3 (10
-8
 M) and 
prostaglandin E2 (10
-7
 M; MP Biomedicals, LLC, Solon, OH, USA) in 100 mm dishes 
pre-coated with type I collagen gel (cell matrix type-IA; Nitta Gelatin, Inc., Osaka, 
Japan) for 7 days. All cells were removed from dishes by treatment with 0.2% 
collagenase (Sigma), replaced in 24 well culture plates and incubated for 6 h. After 
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incubation, PA6 cells were removed by treatment with 0.05% trypsin-EDTA (GIBCO) 
for 5 min. The purity of osteoclasts in this preparation was about 95%. Purified 
osteoclasts spontaneously die due to apoptosis; however, receptor activator of NF-κB 
ligand (RANKL) promotes the survival of purified osteoclasts. The effect of PYC on the 
survival of osteoclasts stimulated with RANKL was examined. Purified osteoclasts were 
then further cultured for 48 h with vehicle (control) and the 200 ng/ml RANKL (Sigma) 
in the presence or absence of PYC. After incubation, cells were fixed and stained for 
TRAP and TRAP-positive multinucleated cells containing more than three nuclei were 
counted as viable osteoclasts. Results were expressed as the mean ± SD of triplicate 
cultures. 
 
Statistical analysis 
Differences between two groups were analyzed using Student’s t test. For comparison of 
more than two groups, analysis of variance (ANOVA) was performed followed by 
Tukey’s test as a post hoc test. A value of p < 0.05 was considered statistically 
significant. 
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RESULTS 
Antibacterial activity against P. gingivalis 
The treatment of P. gingivalis with 1-1000 µg/ml PYC reduced the number of viable 
cells in a dose-dependent and time-dependent manner. After 10 µg/ml, 100 µg/ml or 
1000 µg/ml PYC treatment for 10 min, the number of CFU of P. gingivalis decreased by 
28.4%, 70.4% and 94.1%, respectively. Bactericidal activity against P. gingivalis was 
only observed with 1000 µg/ml PYC treatment for 60 min (Fig. 2), and the number of 
CFU of P. gingivalis decreased from 3.63 ± 0.12 × 10
7
 to 1.02 ± 0.06 × 10
3
. After 
60-min treatment, 1 µg/ml, 10 µg/ml and 100 µg/ml PYC reduced viable cell numbers 
by 18.5%, 43.5% and 76.5%, respectively. 
 
Inhibitory effects of PYC on P. gingivalis adherence and invasion 
Adherence to and invasion of HGEC by P. gingivalis was 5.74 ± 0.67% at an MOI of 
1:100 (Table 1). Addition of PYC to the culture reduced the number of adherent 
bacterial cells in a dose-dependent manner. In particular, 10 µg/ml and 100 µg/ml PYC 
significantly inhibited bacterial adhesion by 64.5% and 84.2%, respectively (p < 0.01). 
Moreover, a remarkable inhibitory effect of PYC on P. gingivalis invasion was observed. 
The addition of 1 µg/ml PYC to the culture resulted in a significant decrease in invasion 
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efficiency by 0.25 ± 0.05% (76.2% relative inhibition) compared with the efficiency 
without PYC (p < 0.01). 
 
Alveolar bone resorption 
No rats showed any obvious signs of systemic illness throughout the study period. The 
animals had similar body weights at the beginning of the experiment and mean body 
weights exhibited a similar rate of increase during the experimental period. At the end 
of the experimental period, mean body weights in groups A, B, C and D were 481.3 ± 
14.7 g, 478.0 ± 30.3 g, 462.0 ± 25.0 g and 446.0 ± 28.4 g, respectively. 
To evaluate the effect of PYC on P. gingivalis-induced alveolar bone resorption, 
bone level differences among the rat groups were determined. Figure 3B shows the 
mean [± standard error of the mean (SEM)] CEJ-ABC distance at each of the seven 
measurement sites. As alveolar bone decreased, the CEJ-ABC distance increased. The 
bone levels of groups A, B, C and D were 0.36 ± 0.03 mm, 0.47 ± 0.03 mm, 0.36 ± 0.02 
mm, and 0.39 ± 0.04 mm, respectively. The bone loss level of group B, which was 
infected with P. gingivalis, was 30.6% greater than that in the non-infected control 
group (p < 0.01), indicating that P. gingivalis infection caused bone resorption. The 
bone level of the P. gingivalis-infected plus PYC administration group (group D) was 
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significantly less than that of the P. gingivalis-infected group (p < 0.01), and the level 
was similar to that of the non-infected controls. Since administration of PYC itself had 
no effect on alveolar bone resorption, these results indicated that administration of PYC 
inhibited P. gingivalis-induced alveolar bone resorption. 
 
Effect of PYC on cell viability 
We performed MTS assays to assess the effect of PYC on PA6 cell viability and to 
determine the appropriate concentration for treating cell cultures. Compared with 
untreated cells, no significant effect on cell viability was shown at a concentration of 
100 μg/ml PYC (Fig. 4). Therefore, PYC was used at a concentration of less than 100 
μg/ml in the osteoclast formation assay. 
 
Inhibitory effect of PYC on osteoclast differentiation 
Co-cultures of PA6 cells and mouse bone marrow cells produced TRAP-positive 
multinucleated osteoclasts in the presence of 1α,25-(OH)2D3 and dexamethasone. 
Treatment with PYC, at concentrations of 1 μg/ml, 10 μg/ml and 100 μg/ml, 
significantly inhibited osteoclast formation by 34.5%, 53.4% and 100.0%, respectively 
(p < 0.01, Fig. 5). Furthermore, addition of 100 μg/ml PYC resulted in complete 
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inhibition of the formation of TRAP-positive cells as well as multinucleated osteoclasts 
(Fig. 5A).  
 
PYC inhibits the survival of osteoclasts 
Purified osteoclasts died spontaneously after an additional 48-h incubation because of 
apoptosis. On the other hand, treatment of the osteoclasts with RANKL (200 ng/ml) 
significantly reduced the number of apoptotic cells and prolonged the cell survival of 
osteoclasts, while maintaining their enormous cell form (Fig. 6A, B). The number of 
TRAP-positive multinucleated osteoclasts with RANKL was approximately 8.4-fold 
higher than that of the control without RANKL treatment. The addition of PYC (1-100 
μg/ml) to the cell cultures with RANKL significantly reduced the number of survived 
osteoclasts in a dose-dependent manner (p < 0.01).  
 
 
DISCUSSION 
Periodontal diseases are chronic inflammatory disorders that lead to the destruction of 
tooth-supporting tissues, including the periodontal ligaments and alveolar bone. These 
diseases are caused by a specific group of Gram-negative anaerobic bacteria (Cochran, 
19 
 
2008; Highfield, 2009; Feng et al., 2006; Haffajee et al., 1994). Among 
periodontopathic bacteria, P. gingivalis, Aggregatibacter actinomycetemcomitans and 
Tannerella forsythia have been reported to cause destructive periodontitis in rodents 
when these microorganisms were given orally (Baker et al., 1994; Evans et al., 1992; 
Schreiner et al., 2003; Sharma et al., 2005). This model is useful to examine the 
preventive and therapeutic effects of drugs and natural compounds, such as plant 
extracts, on periodontal destruction induced by periodontopathic bacteria. 
In this study, we investigated the inhibitory effects of PYC on alveolar bone 
resorption using a rat experimental periodontitis model. PYC administration 
significantly reduced bone resorption induced by P. gingivalis (p < 0.01, Fig. 3B). Since 
plant polyphenols possess potent antimicrobial properties (Pandey et al., 2009; Scalbert 
et al., 2005; El Gharras, 2009), the antibacterial effects of PYC against P. gingivalis 
were examined. The treatment of P. gingivalis with 1-1000 µg/ml PYC reduced the 
number of viable cells in a dose-dependent and a time-dependent manner. Torras et al. 
examined the antimicrobial activity of PYC and found that PYC possessed marked 
bacteriostatic activity against a broad range of microorganisms, including cariogenic 
and periodontopathic bacteria; however, the activity was not microbicidal (Torras et al., 
2005). In our study, bactericidal activity against P. gingivalis was observed with 1000 
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µg/ml PYC treatment for 60 min (Fig. 2), showing that over 99.9% of bacteria were 
killed. The study by Sakanaka et al. showed that green tea polyphenols inhibited the 
growth of P. gingivalis at concentrations of 250-1000 µg/ml, using the purified six 
components of Japanese tea (Sakanaka et al., 1996). Purified constituents of PYC may 
have potent inhibitory effects on P. gingivalis growth. 
Adhesion to host tissue surfaces is the first step in bacterial infection. P. gingivalis 
possesses various adhesion molecules, such as fimbriae, outer membrane proteins and 
polysaccharides (Lamont et al., 2000). Adherent bacteria begin to grow and colonize the 
oral cavity to cause inflammation. As shown in Table 1, PYC (French pine bark extract) 
significantly inhibited adherence to and invasion of human gingival epithelial cells by P. 
gingivalis. Tea extracts were also reported to possess both antibacterial and 
antiadherence activities against P. gingivalis  (Sakanaka et al., 1996; Zhao et al., 2013). 
In our study, a remarkable inhibitory effect of PYC was observed on P. gingivalis 
invasion. Gingival epithelial cells react to bacterial challenges by signaling host 
responses and integrating innate and acquired immune responses (Dale, 2002). Invasive 
bacteria can escape from the host immune system and may lead host cell to destruction. 
Therefore, the inhibitory effects of PYC on adherence to and invasion of epithelial cells 
by P. gingivalis may act as protective measures against oral infection. 
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Recent studies have suggested that the production of reactive oxygen species (ROS) 
may play an important role in the pathogenesis of periodontitis (D’Aiuto et al., 2010; 
Chapple et al., 2007). Stimulation of bacterial antigens induced a large amount of ROS 
production from polymorphonuclear leukocytes, which resulted in the promotion of 
oxidative damage to gingival tissue, periodontal ligaments and alveolar bone. Tomofuji 
et al. (Tomofuji et al., 2009a) suggested that increased levels of oxidative stress due to 
excessive production of ROS are involved in the pathogenesis of periodontitis, and the 
intake of vitamin C, an antioxidant, down-regulated ligature-induced periodontitis 
lesions and gene expression associated with inflammation. They also demonstrated that 
systemic administration of a cocoa-enriched diet, which diminished 
periodontitis-induced oxidative stress, inhibited alveolar bone loss and 
polymorphonuclear leukocytes infiltration in a ligature-induced periodontitis model 
(Tomofuji et al., 2009b). PYC is known to possess potent antioxidant properties 
(Rohdewald, 2002; Packer et al., 1999). Grimm et al. (Grimm et al., 2004) observed 
that PYC metabolite M1 displayed superoxide scavenging activity. Therefore, the 
antioxidant activity of PYC administered orally may have prevented bone resorption in 
the present study. 
Inflammation and bone resorption are main features of periodontal diseases. 
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Bacterial elements stimulate a local inflammatory reaction in gingival tissues, including 
induction of various proinflammatory cytokines production. Interleukin (IL)-1 and 
tumor necrosis factor-alpha (TNF-α) play important roles to stimulate adhesion 
molecules expression which is a necessary step for leukocyte to leave the vascular 
system, the induction of enzymes that degrade connective tissue, and eventually lead to 
alveolar bone loss (Graves et al., 2003; Garlet et al., 2006). Accumulated evidence 
demonstrates anti-inflammatory activity of PYC. Pretreatment of LPS-stimulated RAW 
264.7 cells with PYC reduced both the production of IL-1β ant its mRNA levels (Cho et 
al., 2006). Peng et al. demonstrated that inhibitory effect of PYC on the induction of 
adhesion molecules in TNF-α-treated human vascular endothelial cells (Peng et al., 
2000). The matrix degrading enzyme, such as matrix metalloproteinase 2 (MMP-2) and 
MMP-9, is thought to lead connective tissue breakdown. The research of Grimm et al. 
showed human plasma samples after five days intake of PYC suppressed MMP-9 
release from monocytes stimulated with LPS (Grimm et al., 2006). The 
anti-inflammatory activity of PYC may contribute to suppress alveolar bone resorption. 
Bone resorption can be inhibited in several ways. By reducing the differentiation 
rate of osteoclasts, the number of functionally activated osteoclasts for bone resorption 
can be decreased. It is also possible to inhibit resorptive activity by inducing the 
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apoptosis of mature osteoclasts. Therefore, we examined the inhibitory effect of PYC on 
osteoclastogenesis using an in vitro cell culture assay. Addition of PYC to the culture 
significantly inhibited osteoclast formation at concentrations of 100 μg/ml, 10 μg/ml 
and 1 μg/ml (Fig. 5). Furthermore, the same concentration of PYC showed significant 
inhibition of the number of surviving mature osteoclasts stimulated with RANKL (Fig. 
6). RANKL is a key factor in regulating the process of osteoclast differentiation and 
maintaining the survival of mature osteoclasts. The binding of RANKL to its receptor, 
RANK, triggers the activation of cytoplasmic tumor necrosis factor receptor-associated 
factor 6, which subsequently induces the activation of mitogen-activated protein kinases 
and transcription factors including NF-κB, AP-1 and NFATc1 (Boyle et al., 2003; Lee et 
al., 2003). These transcription factors play a critical role in the regulation of genes 
involved in osteoclast differentiation and the bone resorptive activity of mature 
osteoclasts (Takayanagi et al., 2002). Lin et al. demonstrated that (-)-epigallocatechin 
gallate (EGCG), a major component of the green tea polyphenols, inhibited osteoclast 
differentiation in osteoclast precursor RAW 264.7 cells through the activation of NF-κB 
(Lin et al., 2009). Since a significant inhibitory effect on cell viability of PA6 cells was 
not observed with PYC, the same suppression of signal transduction may result in a 
decrease in the number of osteoclast formed. EGCG was also reported to inhibit 
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survival of osteoclasts differentiated from RAW 264.7 cells (Yun et al., 2007). In this 
study, PYC remarkably inhibited alveolar bone resorption in rat periodontitis. Since 
PYC was administered orally, the effectiveness of PYC for rat periodontitis may be 
caused by the constituents or the metabolites derived from PYC. Further examination is 
necessary, however, the findings from osteoclast culture assays may suggest that the 
ability of PYC to regulate osteoclast formation and survival is associated to the 
inhibition of alveolar bone resorption by PYC. 
In conclusion, we demonstrated that PYC possesses an inhibitory effect on alveolar 
bone resorption in rat periodontitis induced by P. gingivalis infection. We considered 
that PYC suppressed alveolar bone resorption by its antibacterial activity against P. 
gingivalis and by inhibiting osteoclast differentiation and survival. Therefore, PYC may 
be useful as a therapeutic and preventative agent for bone diseases such as periodontitis. 
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FIGURE LEGENDS 
Figure 1. Experimental procedure. Rats were divided into four groups (n = 6/group). 
Group A, control (no challenge with P. gingivalis); group B received an oral challenge 
with P. gingivalis; group C, administered Pycnogenol
®
 mixed in the diet; and group D, 
administered Pycnogenol
®
 and orally infected with P. gingivalis. CFU: colony forming 
units. 
 
Figure 2.  Antibacterial effect of Pycnogenol
®
 (PYC) on P. gingivalis. Bacterial cells 
were treated with PBS (○), 1 μg/ml PYC (△), 10 μg/ml PYC (□), 100 μg/ml PYC (●) or 
1000 μg/ml PYC (■) for the indicated period. 
 
Figure 3. Morphometric bone levels. The distance from the cemento-enamel junction 
(CEJ) to the alveolar bone crest (ABC) was measured at seven buccal sites of the upper 
jaw per rat (A). Values indicate mean bone loss level ± standard error of the mean.  
The level for group B, orally infected with P. gingivalis, was significantly larger than 
that for control group A. Administration of Pycnogenol
®
 in addition to bacterial 
infection significantly inhibited alveolar bone resorption (B). 
**
p < 0.01. 
 
Figure 4. The effect of Pycnogenol
®
 (PYC) on cell viability of MC3T3-G2/PA6 cells. 
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MC3T3-G2/PA6 cells were cultured with various concentrations of PYC for 48 h. 
Results are expressed as the mean ± SD of (n = 5). 
**
p < 0.01, significantly different 
from the untreated control. 
 
Figure 5. Pycnogenol
®
 (PYC) inhibits osteoclast differentiation of BALB/c mouse bone 
marrow cells co-cultured with MC3T3-G2/PA6 cells. (A) Mouse bone marrow cells and 
PA6 cells were co-cultured with 1α,25-dehydroxyvitamin D3 and dexamethasone in the 
presence or absence of PYC at various concentrations. After incubation for 7 days, 
co-cultured cells were stained for tartrate-resistant acid phosphatase (TRAP). 
Arrowheads indicate TRAP-positive multinucleated cells. Bars, 100 μm. (B) 
TRAP-positive multinucleated cells containing three or more nuclei were counted as 
osteoclasts. Results were expressed as the mean ± SD of triplicate cultures. 
**
p < 0.01. 
 
Figure 6. Pycnogenol
®
 (PYC) inhibits the survival of osteoclasts. (A) Purified 
osteoclasts with 200 ng/ml receptor activator of NF-κB ligand (RANKL) were treated 
with PYC extracts for 48 h and stained for tartrate-resistant acid phosphatase (TRAP). 
Bars, 100 μm. (B) TRAP-positive multinucleated cells containing three or more nuclei 
were counted as osteoclasts. Results were expressed as the mean ± SD of triplicate 
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cultures. 
**
p < 0.01. 
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Table 1. Inhibitory effects of Pycnogenol
®
 on P. gingivalis invasion 
              
Pycnogenol 
(μg/ml) 
Bacteria adhering 
and invading
a
 (%) 
Inhibition 
(%) 
Invasion efficiency
b
 
(%) 
Inhibition 
(%) 
0.0  5.74 ± 0.67 - 1.05 ± 0.27 - 
1.0  4.83 ± 0.05 15.9 0.25 ± 0.05
**
 76.2 
10.0  2.04 ± 0.16
**
 64.5 0.13 ± 0.03
**
 87.6 
100.0  0.91 ± 0.27
**
 84.2 0.06 ± 0.0.1
**
 94.3 
       
a
 Defined as the percentage of CFU input that bound to human gingival epithelial cells, 
which represents both adhering and invading.  Values show the means ± standard 
deviations of triplicate cultures. 
b
 Percentage of the P. gingivalis inoculum that entry into epithelial cells.  Values are 
the means ± standard deviations of triplicate cultures. 
**
Significantly different (p < 0.01) from the control values without treatment of 
Pycnogenol. 
 
Figure 1. Experimental procedure. Rats were divided into four groups (n = 6/group). 
Group A, control (no challenge with P. gingivalis); group B received an oral challenge 
with P. gingivalis; group C, administered Pycnogenol® mixed in the diet; and group D, 
administered Pycnogenol® and orally infected with P. gingivalis. CFU: colony forming 
units. 
Figure 2. Morphometric bone levels. The distance from the cemento-enamel junction 
(CEJ) to the alveolar bone crest (ABC) was measured at seven buccal sites of the upper 
jaw per rat (A). Values indicate mean bone loss level ± standard error of the mean.  The 
level for group B, orally infected with P. gingivalis, was significantly larger than that for 
control group A. Administration of Pycnogenol® in addition to bacterial infection 
significantly inhibited alveolar bone resorption (B). **p < 0.01. 
Figure 3.  Antibacterial effect of Pycnogenol® (PYC) on P. gingivalis. Bacterial cells 
were treated with PBS (○), 0.1 μg/ml PYC (△), 1 μg/ml PYC (□), 10 μg/ml PYC (●) 
or 100 μg/ml PYC (■) for the indicated period. 
Figure 4. The effect of Pycnogenol® (PYC) on cell viability of MC3T3-G2/PA6 cells. 
MC3T3-G2/PA6 cells were cultured with various concentrations of PYC for 48 h. Results 
are expressed as the mean ± SD of (n = 5). **p < 0.01, significantly different from the 
untreated control. 
Figure 5. Pycnogenol® (PYC) inhibits osteoclast differentiation of BALB/c mouse bone 
marrow cells co-cultured with MC3T3-G2/PA6 cells. (A) Mouse bone marrow cells and 
PA6 cells were co-cultured with 1α,25-dehydroxyvitamin D3 and dexamethasone in the 
presence or absence of PYC at various concentrations (100 μg/ml, 10 μg/ml, 1 μg/ml or 
0.1 μg/ml). After incubation for 7 days, co-cultured cells were stained for tartrate-resistant 
acid phosphatase (TRAP). Arrowheads indicate TRAP-positive multinucleated cells. Bars, 
100 μm. (B) TRAP-positive multinucleated cells containing three or more nuclei were 
counted as osteoclasts. Results were expressed as the mean ± SD of triplicate cultures. **p 
< 0.01. 
Figure 6. Pycnogenol® (PYC) inhibits the survival of osteoclasts. (A) Purified osteoclasts 
with 200 ng/ml receptor activator of NF-κB ligand (RANKL) were treated with PYC 
extracts (100 μg/ml, 10 μg/ml, 1 μg/ml or 0.1 μg/ml) for 48 h and stained for tartrate-
resistant acid phosphatase (TRAP). Bars, 100 μm. (B) TRAP-positive multinucleated cells 
containing three or more nuclei were counted as osteoclasts. Results were expressed as the 
mean ± SD of triplicate cultures. **p < 0.01. 
